-

SHAREHOLDER ALERT: Robbins LLP Announces That PureCycle Technologies, Inc. (PCT) is Being Sued for Misleading Shareholders

SAN DIEGO & ORLANDO, Fla.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of all purchasers of PureCycle Therapeutics, Inc. (NASDAQ: PCT) and/or Roth CH Acquisition I Co. (ROCH) between November 16, 2020 and May 5, 2021, and all holders of ROCH securities entitled to participate in the March 16, 2021 shareholder vote on the merger with PureCycle. The complaint against the Company and its officers and directors alleges violations of the Securities Exchange Act of 1934 between December 16, 2020 and April 19, 2021. PureCycle provides recycling services.

If you suffered a loss due to the alleged misconduct, click here.

PureCycle Technologies, Inc. (PCT) Made Misstatements Regarding its Purported Financial Condition and Prospects

According to the complaint, on November 16, 2020, PureCycle announced it would list its common stock on NASDAQ through a reverse merger with the ROCH SPAC. At that time, PureCycle claimed it was modeling for its revenue to hit $8 million in 2022 as its first plant came on line. The Company expected revenues to ramp up to $224 million in 2023 with its first five plants and $800 million in 2024. PureCycle also touted the strength of its technology, intellectual property, and management team. Shareholders approved the merger on March 16, 2021.

These statements, however, were false and misleading. Before the market opened on May 6, 2021, Hindenburg Research published a report entitled, "PureCycle: The Latest Zero-Revenue ESG SPAC Charade, Sponsored by The Worst of Wall Street." The Report revealed that the Company's insiders and SPAC sponsors positioned themselves to clear approximately $90 million in case and tradable shares before the Company generates any revenue and that PureCycle's Chairman and CEO, and other associated executives, collectively took six companies public prior to PureCycle, and each failed, among other things. On this news, the Company's share price fell more than 40%, or approximately $10 per share, on May 6, 2021.

If you purchased shares of PureCycle Therapeutics, Inc. (PCT) and/or Roth CH Acquisition I Co. (ROCH) between November 16, 2020 and May 5, 2021, or were entitled to participate in the March 12, 2021 shareholder vote on the merger with PureCycle, you have until July 12, 2021, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against PureCycle Technologies, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...

Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as a “biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.” Pertinent to this action is reproxalap, which is a novel reactive aldehyde species (RASP) inhib...
Back to Newsroom